Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Pancreatic Neoplasms 33Prostatic Neoplasms 31Brain Neoplasms 28Lung Neoplasms 26Neoplasm Metastasis 24Melanoma 21Carcinoma, Hepatocellular 20Breast Neoplasms 17Carcinoma, Renal Cell 12Colorectal Neoplasms 11Squamous Cell Carcinoma of Head and Neck 10Neoplasms 9Small Cell Lung Carcinoma 7Urinary Bladder Neoplasms 5Recurrence 5Head and Neck Neoplasms 5Glioblastoma 5Adenocarcinoma of Lung 5Sarcoma 4Liver Neoplasms 4Kidney Neoplasms 4Uterine Cervical Neoplasms 3NSCLC 3Clear-cell metastatic renal cell carcinoma 3Cholangiocarcinoma 3Uveal Melanoma 2Unresectable Locally Recurrent Rectal Cancer 2Triple Negative Breast Neoplasms 2Rectal Neoplasms 2

Interventions

S 1 (combination) 2Oxaliplatin 2Leucovorin 2Gemcitabine 2Fluorouracil 2130-nm albumin-bound paclitaxel 2zimberelimab 1surufatinib 1Radiosurgery 1Irinotecan 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Locally Advanced Pancreatic Cancer × Radiosurgery × Clear all
NCT06009029 2023-08-24

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

Peking University Third Hospital

Phase 2 Not yet recruiting
96 enrolled
Gastrointestinal

Locally Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡